留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

凝血异常在HBV相关慢加急性肝衰竭患者血栓形成中的作用

徐英 黄小平 陈丽 孙蔚 王艳 甘建和

徐英, 黄小平, 陈丽, 等. 凝血异常在HBV相关慢加急性肝衰竭患者血栓形成中的作用[J]. 临床肝胆病杂志, 2021, 37(3): 560-564. DOI: 10.3969/j.issn.1001-5256.2021.03.012
引用本文: 徐英, 黄小平, 陈丽, 等. 凝血异常在HBV相关慢加急性肝衰竭患者血栓形成中的作用[J]. 临床肝胆病杂志, 2021, 37(3): 560-564. DOI: 10.3969/j.issn.1001-5256.2021.03.012
XU Y, HUANG XP, CHEN L, et al. Role of coagulation abnormalities in thrombosis in patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(3): 560-564. DOI: 10.3969/j.issn.1001-5256.2021.03.012
Citation: XU Y, HUANG XP, CHEN L, et al. Role of coagulation abnormalities in thrombosis in patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(3): 560-564. DOI: 10.3969/j.issn.1001-5256.2021.03.012

凝血异常在HBV相关慢加急性肝衰竭患者血栓形成中的作用

DOI: 10.3969/j.issn.1001-5256.2021.03.012
基金项目: 

国家科技部“十三五”重大专项 2017ZX10203201002-002

详细信息
    作者简介:

    徐英(1986—),女,主治医师,主要从事肝衰竭和重症疑难肝病的诊治研究

    通讯作者:

    甘建和,ganjianhe@aliyun.com

  • 利益冲突声明:本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突,特此声明。
  • 作者贡献声明:徐英、黄小平负责课题设计,资料分析,撰写论文;陈丽、孙蔚、王艳参与收集数据,修改论文;徐英、甘建和负责拟定写作思路,指导撰写文章并最后定稿。
  • 中图分类号: R512.62;R575.3

Role of coagulation abnormalities in thrombosis in patients with hepatitis B virus-associated acute-on-chronic liver failure

  • 摘要:   目的  观察传统凝血功能和血小板相关指标对HBV相关慢加急性肝衰竭(HBV-ACLF)患者血栓形成事件的作用。  方法  选取2015年1月—2019年12月在苏州大学附属第一医院住院的HBV-ACLF患者56例,分为发生血栓组(n=24)与未发生血栓组(n=32)。回顾性分析两组患者入院时的一般临床资料,观察入院后第1~7天的凝血功能,血小板计数和血小板功能相关指标平均血小板体积(MPV)的变化。符合正态分布的计量资料两组间比较采用t检验,不符合正态分布的计量资料两组间比较采用Mann-Whitney U秩和检验;计数资料两组间比较采用χ2检验。采用重复测量资料方差分析比较组内及组间不同时间凝血指标的差异。  结果  HBV-ACLF患者在入院时,发生血栓组年龄31.5(29.0~34.0)岁,较未发生血栓组年龄48.5(36.0~50.7)岁小,差异有统计学意义(Z=-2.637,P=0.008);在入院当天,MPV在发生血栓组与未发生血栓组间差异无统计学意义(P>0.05)。在入院后第2~7天,MPV值发生血栓组与未发生血栓组间差异均有统计学意义(t值分别为-2.696、-2.742、-2.894、-4.174、-3.945、-4.716,P值均<0.01)。发生血栓组MPV的峰值为入院第5天,均值为(13.90±1.12)fl,高于正常值范围。所有纳入患者在入院时,PT均值为(28.8±7.2)s、APTT均值(50.5±8.7)s、INR均值(2.6±0.7),均高于正常值;Fb均值为(1.16±0.3)g/L、血小板计数均值为(107.7±26.5)×109/L,均低于正常值。而PT、APTT、Fbg、INR及血小板计数在发生血栓组与未发生血栓组间差异均无统计学意义(P值均>0.05)。  结论  肝衰竭患者凝血功能障碍,更多是一种低平衡状态,是复杂与异质性的,需要个体化处理。HBV-ACLF患者中,易发生血栓事件者可能与血小板的功能有关,而与血小板计数及凝血常规指标关系不大。
  • 图  1  患者入院后凝血相关指标随时间(第1~7天)变化概况

    注:a,PT、APTT随时间变化;b,Fb、INR随时间变化;c,血小板计数、MPV随时间变化。

    图  2  MPV在血栓发生与否组间的水平比较

    表  1  患者一般临床资料与血制品使用情况

    指标 NTC组(n=32) TC组(n=24) 统计值 P
    年龄(岁) 48.5(36.0~50.7) 31.5(29.0~34.0) Z=-2.637 0.008
    性别(男/女) 20/12 15/9 χ2=-1.236 0.216
    血小板计数(×109/L) 102.5(87.2~128.7) 91.0(58.0~124.0) Z=-1.127 0.260
    MPV(fl) 12.1(11.6~12.9) 13.2(12.6~14.8) Z=-1.128 0.259
    NH3(μmol/L) 67.1(47.7~81.5) 122.8(97.1~148.5) Z=-3.755 <0.001
    Alb(g/L) 31.4(27.4~35.9) 30.8(29.3~32.3) Z=0 1.000
    Cr(μmol/L) 55.3(48.3~72.6) 54.1(42.4~65.8) Z=-1.127 0.260
    BUN(mmol/L) 3.8(3.0~5.1) 3.9(3.8~4.0) Z=-0.567 0.571
    TBil(μmol/L) 298.5(209.6~353.7) 219.4(158.8~280) Z=-2.253 0.024
    MELD评分 28.5(23.3~30.0) 25.5(23.0~28.0) Z=-1.514 0.130
    入院时凝血指标
      PT(s) 30.2(22.5~33.0) 26.8(24.3~29.3) Z=-1.502 0.133
      APTT(s) 52.6(43.1~58.9) 44.4(39.3~49.5) Z=-2.623 0.008
      Fb(g/L) 1.10(0.90~1.40) 0.90(0.98~1.01) Z=-1.878 0.620
      INR 2.7(2.0~3.1) 2.4(2.1~2.6) Z=-1.502 0.133
    住院期间输注血液制品情况
      新鲜冰冻血浆
        ≥1000 ml[例(%)] 29(90.6) 18(75.0) χ2=1.459 0.227
        中位数 6400(3000~12 500) 5000(5000~13 500) Z=-0.141 0.888
      冷沉淀(u)
        例数(%) 3(9.3) 3(12.5) χ2=0.000 1.000
        中位数 7.5(3.8~9.0) 6.0(3.0~8.0) Z=-0.373 0.709
      血小板(u)
        例数(%) 7(21.8) 6(25.0) χ2=0.075 0.784
        中位数 30.0(12.5~55.0) 20.0(12.5~40.0) Z=-0.781 0.435
      红细胞(u)
        例数(%) 10(34.3) 9(37.5) χ2=0.239 0.625
        中位数 6.0(4.0~8.5) 6.0(4.0~8.0) Z=-0.501 0.959
    血浆置换[例(%)] 16(50.0) 15(62.5) χ2=0.867 0.352
      注:Fb,纤维蛋白原。
    下载: 导出CSV

    表  2  TC组与NTC组ACLF患者凝血功能与血小板指数变化比较

    指标 第1天 第2天 第3天 第4天 第5天 第6天 第7天 F P
    PT(s)
      NTC组 29.2±7.5 24.0±5.7 23.6±6.8 22.7±3.9 22.6±3.6 24.0±4.4 26.6±10.1 10.9621) <0.0011)
      TC组 26.0±3.5 24.0±2.7 22.9±0.6 24.2±0.4 24.7±2.2 23.4±2.6 26.1±2.1 1.9951) 0.2011)
      t 1.181 0.044 0.294 -1.048 -1.543 0.416 0.125 0.0222) 0.8822)
      P 0.243 0.965 0.770 0.299 0.129 0.679 0.901 0.8883) 0.4393)
    APTT(s)
      NTC组 51.5±8.8 61.6±35.0 59.3±16.0 67.3±37.5 78.3±40.6 63.8±22.7 78.4±34.6 6.1841) <0.0011)
      TC组 44.7±5.1 60.5±16.0 65.6±24.5 69.7±27.2 67.8±22.0 81.5±28.3 70.0±5.7 6.4911) 0.0381)
      t 2.115 0.090 -0.946 -0.175 0.714 -1.968 0.681 0.0002) 0.9902)
      P 0.039 0.929 0.348 0.861 0.478 0.054 0.499 0.9873) 0.4093)
    Fb(g/L)
      NTC组 1.20±0.30 1.10±0.45 1.10±0.52 1.10±0.48 0.90±0.38 0.90±0.37 0.80±0.52 16.1311) <0.0011)
      TC组 1.00±0.01 1.10±0.14 0.70±0.27 0.80±0.1 0.80±0.22 0.90±0.05 0.70±0.01 13.4731) 0.0081)
      t 1.783 0.098 2.122 1.821 0.880 -0.160 0.524 1.4362) 0.2362)
      P 0.080 0.992 0.038 0.074 0.383 0.874 0.603 2.8653) 0.0443)
    INR
      NTC组 2.70±0.72 2.30±0.65 2.30±0.78 2.10±0.44 2.10±0.4 2.40±0.78 2.50±0.97 8.6551) <0.0011)
      TC组 2.40±0.28 2.10±0.27 1.80±0.18 2.00±0.11 2.10±0.11 2.00±0.12 1.90±0.32 8.3451) 0.0231)
      t 1.162 0.788 1.724 0.448 -0.439 1.298 1.821 2.2532) 0.1392)
      P 0.250 0.434 0.090 0.656 0.663 0.200 0.074 1.7243) 0.1653)
    血小板计数(×109/L)
      NTC组 104±26 95±24 85±24 76±25 61±28 56±26 47±24 145.7051) <0.0011)
      TC组 97±29 73±5 60±3 54±4 66±28 50±19 56±16 5.6721) <0.0011)
      t 0.655 2.543 2.966 2.483 -0.400 0.574 -1.045 1.1492) 0.2342)
      P 0.515 0.014 0.004 0.016 0.691 0.569 0.301 7.3213) 0.0013)
    MPV(fl)
      NTC组 12.1±1.3 11.8±1.3 11.4±1.8 11.4±1.8 11.8±1.3 11.9±1.2 11.4±1.4 6.7181) <0.0011)
      TC组 13.2±2.4 13.4±2.2 13.2±1.5 13.4±2.0 13.9±1.1 13.7±0.6 13.8±0.5 1.0741) 0.3351)
      t -1.916 -2.696 -2.742 -2.894 -4.174 -3.945 -4.716 13.9142) <0.0012)
      P 0.061 0.009 0.008 0.005 <0.001 <0.001 <0.001 1.7363) 0.1623)
      注:1)不同时间比较;2)不同组间比较;3)时间与血栓形成的交互作用。
    下载: 导出CSV
  • [1] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.01.007

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007
    [2] VIOLI F, BASILI S, RAPARELLI V, et al. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?[J]. J Hepatol, 2011, 55(6): 1415-1427. DOI: 10.1016/j.jhep.2011.06.008
    [3] DABBAGH O, OZA A, PRAKASH S, et al. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease[J]. Chest, 2010, 137(5): 1145-1149. DOI: 10.1378/chest.09-2177
    [4] AGARWAL B, WRIGHT G, GATT A, et al. Evaluation of coagulation abnormalities in acute liver failure[J]. J Hepatol, 2012, 57(4): 780-786. DOI: 10.1016/j.jhep.2012.06.020
    [5] WARRILLOW S, FISHER C, TIBBALLS H, et al. Coagulation abnormalities, bleeding, thrombosis, and management of patients with acute liver failure in Australia and New Zealand[J]. J Gastroenterol Hepatol, 2020, 35(5): 846-854. DOI: 10.1111/jgh.14876
    [6] HABIB M, ROBERTS LN, PATEL RK, et al. Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation[J]. Liver Int, 2014, 34(5): 672-678. DOI: 10.1111/liv.12369
    [7] ALLISON MG, SHANHOLTZ CB, SACHDEVA A. Hematological issues in liver disease[J]. Crit Care Clin, 2016, 32(3): 385-396. DOI: 10.1016/j.ccc.2016.03.004
    [8] BLASI A. Coagulopathy in liver disease: Lack of an assessment tool[J]. World J Gastroenterol, 2015, 21(35): 10062-10071. DOI: 10.3748/wjg.v21.i35.10062
    [9] LYU BY, LI Q. Strategies in the evaluation of coagulation status in patients with liver failure[J]. J Clin Hepatol, 2020, 36(4): 928-931. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.04.049

    吕滨月, 李谦. 肝衰竭患者的出凝血状态评估策略[J]. 临床肝胆病杂志, 2020, 36(4): 928-931. DOI: 10.3969/j.issn.1001-5256.2020.04.049
    [10] STRAVITZ RT, ELLERBE C, DURKALSKI V, et al. Bleeding complications in acute liver failure[J]. Hepatology, 2018, 67(5): 1931-1942. DOI: 10.1002/hep.29694
    [11] YIN JB, NIU Y, QIAN LY, et al. Mean platelet volume predicts survival in patients with hepatocellular carcinoma and type 2 diabetes[J]. Diabetes Res Clin Pract, 2019, 151: 120-127. DOI: 10.1016/j.diabres.2019.04.012
    [12] MADAN SA, JOHN F, Pitchumoni CS. Nonalcoholic fatty liver disease and mean platelet volume: A systemic review and Meta-analysis[J]. J Clin Gastroenterol, 2016, 50(1): 69-74. DOI: 10.1097/MCG.0000000000000340
    [13] POKORA RODAK A, KICIAK S, TOMASIEWICZ K. Neutrophil-lymphocyte ratio and mean platelet volume as predictive factors for liver fibrosis and steatosis in patients with chronic hepatitis B[J]. Ann Agric Environ Med, 2018, 25(4): 690-692. DOI: 10.26444/aaem/99583
    [14] KISACIK B, TUFAN A, KALYONCU U, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis[J]. Joint Bone Spine, 2008, 75(3): 291-294. DOI: 10.1016/j.jbspin.2007.06.016
    [15] YATES KR, WELSH J, ECHRISH HH, et al. Pancreatic cancer cell and microparticle procoagulant surface characterization: Involvement of membrane-expressed tissue factor, phosphatidylserine and phosphatidylethanolamine[J]. Blood Coagul Fibrinolysis, 2011, 22(8): 680-687. DOI: 10.1097/MBC.0b013e32834ad7bc
    [16] EXNER T, JOSEPH JE, CONNOR D, et al. Increased procoagulant phospholipid activity in blood from patients with suspected acute coronary syndromes: A pilot study[J]. Blood Coagul Fibrinolysis, 2005, 16(5): 375-379. DOI: 10.1097/01.mbc.0000173465.45613.a3
    [17] BRAEKKAN SK, MATHIESEN EB, NJ lSTAD I, et al. Mean platelet volume is a risk factor for venous thromboembolism: The tromsø study, tromsø, norway[J]. J Thromb Haemost, 2010, 8(1): 157-62. DOI: 10.1111/j.1538-7836.2009.03498.x
    [18] LISMAN T, BONGERS TN, ADELMEIJER J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity[J]. Hepatology, 2006, 44(1): 53-61. DOI: 10.1002/hep.21231
    [19] O'SHAUGHNESSY DF, ATTERBURY C, BOLTON MAGGS P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant[J]. Br J Haematol, 2004, 126(1): 11-28. DOI: 10.1111/j.1365-2141.2004.04972.x
    [20] SEGAL JB, DZIK WH, Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: An evidence-based review[J]. Transfusion, 2005, 45(9): 1413-1425. DOI: 10.1111/j.1537-2995.2005.00546.x
  • 加载中
图(2) / 表(2)
计量
  • 文章访问数:  72
  • HTML全文浏览量:  15
  • PDF下载量:  21
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-09-09
  • 修回日期:  2020-10-28
  • 刊出日期:  2021-03-16
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回